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The extraordinary advances in cardiac surgery, intensive
care, and noninvasive diagnosis over the last 50 years have
led to an enormous growth in the U.S. and throughout the
world in the number of adults with congenital heart disease
(CHD). Approximately 85% of babies born with cardiovas-
cular anomalies can expect to reach adulthood, and with
continued improvement in surgical technique, this could
increase further in the next two decades (1). In Canada, it is
estimated that the number of survivors with adult congenital
heart disease (ACHD) will increase from 94,000 in 1996 to
124,000 by the end of 2006. Although there is a general
recognition that there are large numbers of adults with
CHD in the U.S., accurate statistics are lacking. Reported
prevalence rates of CHD in newborns vary widely and
depend, to some extent, on lesion inclusion and exclusion
criteria. For example, some studies include ventricular septal
defects (VSDs); however, about two thirds of these individ-
uals no longer have a VSD by adult age. Many studies
exclude bicuspid aortic valves, which are present in 1% of
live births. In addition, different methods of ascertainment
(e.g., physical examination, echocardiography, registry data)
yield varying prevalence rates of CHD in infancy.
A recent English study (2) reviewed all births in one
health region (Newcastle) between 1985 and 1994, and
noted 1,942 cases of CHD in a population of 377,310 live
births (incidence of 5.2 per 1,000). Of these newborns,
1,514 were predicted to survive $16 years. Because addi-
tional diagnoses are sometimes made later in childhood, at
least 2,192 children were expected to survive $16 years.
Also, an estimated 784 would require follow-up in adult life.
These figures predict the need for follow-up of adults with
CHD, for .200 cases per 100,000 live births, or .1,600
cases every year in the U.K. (assuming a population of 50
million). Assuming a population of 280 million in the U.S.,
that would mean an increase of 8,960 adult cases annually,
or 89,600 cases in the current decade.
Most studies from the mid 1980s onward, however, as
well as more recent Canadian studies, report the number of
CHD births to be close to 10 in 1,000 live births (3).
Defining the exact size and composition of this population
in adulthood is challenging, because data are lacking. An
important mandate of this Bethesda Conference is to
estimate patient numbers, which are essential for program
planning and resource allocation. On the basis of the U.S.
census data, the documented birth rates from 1940 to 1989
were averaged (Tables 1–3). The diagnoses corresponding
to complex, moderate, and mild lesions are shown in Tables
4 through 6, and are those used by Task Force 4. Based on
a documented incidence of 1.5 in 1,000 live births for
complex CHD (Table 1) and by extrapolating likely survival
rates for the early through more recent years, the approxi-
mate numbers of survivors in this group were derived. The
incidence of 1.5 in 1,000 live births was based on the large
New England Regional Infant Cardiac Program (NERICP)
review of catheterization data, surgical findings, and post-
mortem diagnoses (4). Using this approach, ;117,000
adults with truly complex CHD are estimated to live in the
U.S. in the year 2000. With improved surgical techniques, this
number can be anticipated to increase over the next decade.
Using a similar model, Table 2 demonstrates the antici-
pated survival, to the year 2000, of patients with moderate
CHD, as defined in Table 5. A prevalence of 2.5 in 1,000 is
derived from published data on children, as well as some
patients who began with more simple lesions but acquired
complications (e.g., VSD with valve lesions, patent ductus
arteriosus causing left heart dilation) (Table 7). These
estimates predict an adult population of 302,000 with
moderate CHD by the year 2000 in the U.S.
Estimating the number of adult patients with simple
CHD (Tables 3 and 6) is more difficult. To utilize the
absolute prevalence of simple lesions detected in infancy
would grossly overestimate the number of adult survivors,
because most VSDs will have closed by adulthood, and
these patients will no longer be considered to have CHD.
Thus, there will be considerable “attrition” of the numbers
of patients with VSDs between the incidence at birth and
the prevalence in adulthood. Most patients with a patent
ductus arteriosus will undergo surgical or spontaneous
closure in childhood (by definition, therefore, remaining
“simple”), but a small proportion will remain patent, many
needing closure, and are therefore defined as “moderate”
cases. By utilizing these assumptions (Table 7), the preva-
lence of these lesions is derived: ;2.2 in 1,000. Thus, the
estimated survival of patients with simple CHD in the U.S.
to the year 2000 is 368,800. A conservative estimate of the
total number of survivors—combining the mild, moderate,
and complex subgroups—is 787,800. The addition of those
with isolated bicuspid aortic valves would dramatically
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increase this number. The moderate and complex sub-
groups—totaling 419,000 patients—need periodic (e.g.,
every 6–24 months) follow-up in a regional ACHD center.
These figures may well be underestimates for two impor-
tant reasons. First, they are based on the incidence of CHD
presenting in infancy and childhood, but at least 10% of
cases seen in an ACHD clinic (in particular, secundum
atrial septal defect, Ebstein’s anomaly, and congenitally
corrected transposition) are not diagnosed until adulthood.
In addition, increasing numbers of immigrants to the U.S.
add to the patient population. Therefore, a conservative
estimate of patients needing periodic follow-up at a regional
ACHD center is ;400,000. Although these predictions,
again, are based on several assumptions, they provide a
framework to estimate current and future resource require-
ments necessary to provide optimal care.
This population growth is also reflected in the growth of
individual regional ACHD centers. In Toronto, a 269%
expansion in the outpatient work load was noted over a
10-year period between 1987 and 1997. Similarly, an
increase in the number of admissions to a large ACHD unit
in the U.K. is shown in Figure 1. Notably, these admissions
continue to increase, particularly for patients .30 years of age;
by 1996, 30% of patients admitted were .40 years of age.
DISEASE PATTERNS
Data on the basic diagnosis and age of outpatients in a large
unit in the U.K. in 1997 are also presented (Figs. 2 and 3).
Complex lesions, such as tricuspid atresia and single-
ventricle physiology, are well represented in patients .20
years of age, particularly in those .30 years of age, in
current ACHD centers. The age range of patients seen in
two large clinics is shown in Figure 4; they were older in the
Mayo Clinic than in the Toronto series, where 50% versus
30% of patients were $40 years of age. These more complex
patients are obviously vulnerable to additional acquired
co-morbidities that impact both their cardiac and medical
care, including hypertension, pulmonary, renal, and myo-
cardial disease, and coronary artery disease. It is estimated
that ;55% of the adult patient population is at medium to
high-risk (defined as those at significant risk for premature
death, re-operation, and complications) and thus need to be
seen regularly in ACHD regional centers and followed for
life. These patients include those with atresia, single-
ventricle physiology, transposition variants, Ebstein’s anom-
aly, tetralogy of Fallot, pulmonary vascular disease, and
complex septal defects. Periodic review at a regional ACHD
center continues to offer advantages over a general cardiac
evaluation, particularly regarding the timing and type of
intervention, follow-up strategy, and general recommenda-
tions (5). Approximately 45% of patients with mild defects,
such as a small VSD or mild pulmonary valve stenosis, will
not require regular follow-up in a regional ACHD center,
but might benefit from at least one review at such a center
at the discretion of the patient’s physician.
The profile of this patient population will change over the
next few decades, not only because of advancing age, but
also with improved survival of patients with complex anom-
alies. In addition, with the impetus to perform definitive
repair at an earlier age and with changing operative proce-
dures, there will be changes in the anticipated disease
patterns. Many adult survivors will have different hemody-
namic and cardiac problems from those currently seen. For
example, an infant with transposition of the great arteries
Table 1. Estimated Prevalence of Complex Congenital Heart Disease in the U.S.
Year
of Birth
Birth Rate/
Years
Prevalence
(1.5/1,000)
Survival Rate
(First Year)
Survival Rate
(to Year 2000)
1940–1959 3 million
3 20 years
4,500
90,000
20%
18,000
10%
9,000
1960–1979 4 million
3 20 years
6,000
120,000
65%
78,000
50%
60,000
1980–1989 4 million
3 10 years
6,000
60,000
85%
51,000
80%
48,000
Totals 147,000 117,000
Table 2. Estimated Prevalence of Moderate Congenital Heart Disease in the U.S.
Year
of Birth
Birth Rate/
Years
Prevalence
(2.5/1,000)
Survival Rate
(First Year)
Survival Rate
(to Year 2000)
1940–1959 3 million
3 20 years
7,500
150,000
60%
90,000
55%
82,500
1960–1979 4 million
3 20 years
10,000
200,000
70%
140,000
65%
130,000
1980–1989 4 million
3 10 years
10,000
100,000
90%
90,000
90%
90,000
Totals 320,000 302,500
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will no longer have a Mustard or Senning procedure (with
its late problems of systemic ventricular dysfunction and
arrhythmias), but might be anticipated to have an arterial
switch procedure and encounter quite different cardiac
sequelae in adult life. Patients with complex single-ventricle
physiology and various modifications of the Fontan proce-
dure will increase in number. Perhaps with refinements in
noninvasive diagnosis and earlier definitive repair of shunt
lesions, the prevalence of pulmonary vascular disease and
Eisenmenger syndrome in the adult population could be
expected to diminish. These patients with complex malfor-
mations are subject to more diverse and numerous late
complications and must be seen regularly at a regional
ACHD center, to which they should have direct access.
They need more intensive follow-up and probably more
frequent re-evaluations and interventions.
SPECIAL RESOURCES
Impact of cardiac surgery. In the largest congenital cardiac
center in the U.K., one in five admissions was for cardiac
surgery. The Society of Cardiothoracic Surgeons of the
U.K. Registry for 1998/1999 reports that in the U.K., 3,836
congenital heart operations were performed, with a mortal-
ity rate of 4.7%. There were 339 patients $16 years of age,
with a mortality rate of 2.1%, but the data were not stratified
according to low- and high-volume units, nor were they
audited.
Some centers reported a surprisingly low number of
ACHD operations per year, although expertise is often
focused in centers where the same surgeons operate on both
pediatric and adult patients, so the numbers can be com-
bined. Previously published data from Stark et al. (6) have
shown that mortality is higher in centers with lower
operative volume, highlighting the risk of performing the
“occasional” operation on adult patients with CHD.
It is estimated in the U.S. that 20,000 operations for
CHD are performed every year. Based on pediatric data,
low-volume centers have a higher mortality. The outcome is
likely to be worse for adult patients who do not always have
the benefit of a surgeon with special expertise and training
in CHD. It is important, both medically and financially, to
concentrate resources and funding and place patients in
specialized centers. A close collaboration is necessary be-
tween experienced and trained cardiologists, echocardio-
Table 3. Estimated Prevalence of Simple Congenital Heart Disease in the U.S.
Year
of Birth
Birth Rate/
Years
Prevalence
(2.2/1,000)
Survival Rate
(First Year)
Survival Rate
(to Year 2000)
1940–1959 3 million
3 20 years
6,600
132,000
95%
125,400
90%
118,000
1960–1979 4 million
3 20 years
8,800
176,000
95%
167,200
95%
167,200
1980–1989 4 million
3 10 years
8,800
88,000
95%
83,600
95%
83,600
Totals 376,200 368,800
Table 4. Types of Adult Patients With Congenital Heart
Disease of Great Complexity*
Conduits, valved or nonvalved
Cyanotic congenital heart (all forms)
Double-outlet ventricle
Eisenmenger syndrome
Fontan procedure
Mitral atresia
Single ventricle (also called double inlet or outlet, common or primitive)
Pulmonary atresia (all forms)
Pulmonary vascular obstructive diseases
Transposition of the great arteries
Tricuspid atresia
Truncus arteriosus/hemitruncus
Other abnormalities of atrioventricular or ventriculoarterial connection
not included above (i.e., crisscross heart, isomerism, heterotaxy
syndromes, ventricular inversion)
*These patients should be seen regularly at adult congenital heart disease centers.
Modified from Connelly MS, et al. Canadian Consensus Conference on Adult
Congenital Heart Disease, 1996. Can J Cardiol 1998;14:395–452.
Table 5. Types of Adult Patients With Congenital Heart
Disease of Moderate Severity*
Aorto-left ventricular fistulae
Anomalous pulmonary venous drainage, partial or total
Atrioventricular canal defects (partial or complete)
Coarctation of the aorta
Ebstein’s anomaly
Infundibular right ventricular outflow obstruction of significance
Ostium primum atrial septal defect
Patent ductus arteriosus (not closed)
Pulmonary valve regurgitation (moderate to severe)
Pulmonic valve stenosis (moderate to severe)
Sinus of Valsalva fistula/aneurysm
Sinus venosus atrial septal defect
Subvalvar or supravalvar aortic stenosis (except HOCM)
Tetralogy of Fallot
Ventricular septal defect with
Absent valve or valves
Aortic regurgitation
Coarctation of the aorta
Mitral disease
Right ventricular outflow tract obstruction
Straddling tricuspid/mitral valve
Subaortic stenosis
*These patients should be seen periodically at regional adult congenital heart disease
centers. Modified from Connelly MS, et al. Canadian Consensus Conference on
Adult Congenital Heart Disease, 1996. Can J Cardiol 1998;14:395–452.
HOCM 5 hypertrophic obstructive cardiomyopathy.
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graphers, interventional cardiologists, surgeons, and anes-
thesiologists, with well-trained nurses on every team. The
expert surgical care provided to children with cardiac anom-
alies must also be provided to adults. Re-operations are
frequent, and the overall mortality is higher in patients
having a re-operation versus a first operation (7). In one
U.S. center (Mayo Clinic) following .1,800 patients, 1,243
of whom had cardiac surgery, almost 50% had two or more
operations and 290 (23%) had three or more operations.
This necessity for re-operation (particularly in patients with
bioprosthetic valves and extracardiac conduits), again em-
phasizes the need for special surgical expertise in CHD. The
types of operations in adult patients in a single center (Mayo
Clinic) by diagnosis and age are shown in Table 8.
Operative mortality varies according to the basic diagno-
sis, the type of surgical repair, and the complexity of the
anatomy. Re-operation poses technical difficulties for the
surgeon because of adhesions (especially between the heart,
aorta or conduit, and sternum), lack of retrosternal space,
loss of anatomic landmarks (especially the coronary arteries)
or the development of collateral vessels. In addition, there
may be deleterious effects of all previous bypass operations
on long-term myocardial function. Cyanotic patients face a
higher mortality and more postoperative complications.
Increasing age is associated with a higher mortality because
additional co-morbid factors (as outlined previously) in-
crease the operative risk. A detailed preoperative evaluation
performed by an experienced medical and surgical team is
essential. Transthoracic and transesophageal echocardiogra-
phy, cardiac catheterization, and magnetic resonance imag-
ing are necessary complementary tools to help the physi-
cians make appropriate decisions. Holter monitoring and
electrophysiologic study may determine if significant ar-
rhythmias are present. Adults often report that they are
asymptomatic as they adapt to their chronic condition and
do not exercise beyond their limits. Exercise testing, critical
evaluation of the patient’s functional class, and assessment
of ventricular function will help to determine the timing,
risk, and success of the operation.
Transplantation is sometimes needed when the cardiac
anatomy is not suitable for an operation or when ventricular
dysfunction is too severe. The indications for transplanta-
tion are similar to those in patients with other cardiac
conditions, and should be considered in patients who have
New York Heart Association functional class IV symptoms,
despite optimal medical therapy and in the absence of other
therapeutic options. The number of adults with CHD
requiring heart transplantation is currently relatively small,
and an even smaller group has been reported with heart and
Figure 1. Age range of patients with CHD at hospital admission in a
single center from 1975 onwards. The unit was opened as an adolescent
unit in 1975 at the National Heart Hospital, joined by the Royal Brompton
Hospital in 1990. Statistics from Jane Somerville, London, U.K.
Figure 2. Outpatient attendance for 1997, according to age .16 years,
basic diagnosis, and age. AR 5 aortic regurgitation; AS 5 aortic stenosis;
ASD 5 atrial septal defect; PV 5 pulmonary valve; TGA 5 transposition
of the great arteries; VSD 5 ventricular septal defect. Statistics from Jane
Somerville, London, U.K.
Table 7. Estimated Prevalence of Simple Congenital Heart
Lesions in Infancy, as Compared With Prevalence in Adulthood
Prevalence in Infancy
(per 1,000)
Estimated Prevalence of Simple
Lesions in Adulthood
(per 1,000)
VSD* 3 0.3
PDA† 0.6 0.5
ASD‡ 0.9 0.6
PS§ 0.6 0.5
AS 0.3 0.3
Totals 5.4 2.2
*Most ventricular septal defects (VSDs) are closed by adulthood and are no longer a
problem (i.e., the patients no longer have a “lesion”). †Most patent ductus arteriosi
(PDAs) close spontaneously or are closed in childhood, and therefore remain in the
“simple” category. ‡Most atrial septal defects (ASDs) are closed in childhood, and
therefore remain in the “simple” category. §Most pulmonary stenoses (PS) remain in
the “simple” category; some will become moderate or severe; and some will develop
pulmonary regurgitation, and therefore be defined as “moderately complex.”
AS 5 aortic stenosis.
Table 6. Types of Adult Patients With Simple Congenital
Heart Disease*
Native disease
Isolated congenital aortic valve disease
Isolated congenital mitral valve disease (e.g., except parachute valve,
cleft leaflet)
Isolated patent foramen ovale or small atrial septal defect
Isolated small ventricular septal defect (no associated lesions)
Mild pulmonic stenosis
Repaired conditions
Previously ligated or occluded ductus arteriosus
Repaired secundum or sinus venosus atrial septal defect without
residua
Repaired ventricular septal defect without residua
*Those patients can usually be cared for in the general medical community.
Modified from Connelly MS, et al. Canadian Consensus Conference on Adult
Congenital Heart Disease, 1996. Can J Cardiol 1998;14:395–452.
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lung transplantation. Transplantation in adults with CHD
has been most frequently performed in patients with
Fontan-type repair, transposition of the great arteries after a
Mustard or Senning procedure with severe systemic (mor-
phologically right) ventricular dysfunction, congenitally cor-
rected transposition with ventricular dysfunction, severe
Ebstein’s anomaly or Eisenmenger syndrome. Transplanta-
tion needs may also increase in the next two decades, as
more children with complex single-ventricle physiology
undergo Fontan-like repair.
Electrophysiology. There is a growing recognition that
arrhythmias, both atrial and ventricular, are an increasing
problem in terms of management in these patients, and they
are often associated with increasing morbidity and mortal-
ity. This is a consequence of: 1) underlying anatomic
abnormalities; 2) chamber dilation and progressive fibrosis;
3) previous surgical incisions; and 4) compromised hemo-
dynamic status. Pharmacologic management options for
these patients may be limited by concomitant sinus node
dysfunction, significant associated systemic ventricular dys-
function, and the desire for pregnancy.
Over last few years, newer, nonpharmacologic manage-
ment options have emerged, specifically: 1) catheter abla-
tion; 2) surgical approaches targeting structural abnormali-
ties as well as offering intraoperative electrophysiologic
ablation; and 3) automatic implantable internal defibrillators
and a new generation of pacemakers with algorithms de-
signed to prevent and treat atrial tachyarrhythmias. With
some exceptions, in this population catheter ablation has
met with only modest success so far; it is anticipated that
ongoing refinements of mapping and ablation techniques
will result in improved outcomes. A combined surgical
approach has been employed successfully in the manage-
ment of atrial arrhythmias, including those in patients with
Ebstein’s anomaly and patients undergoing Fontan revision,
including the arrhythmias (both atrial and ventricular) seen
after tetralogy of Fallot repair.
These approaches, again, emphasize the desirability of a
closely integrated collaboration between the surgeon, elec-
trophysiologist, and cardiologist. With refinements in med-
ical and nonpharmacologic therapy, it is anticipated that the
need for arrhythmia therapy will increase in this aging
population. The newer generation of atrial antitachycardia
pacemakers and/or defibrillators will hopefully offer an
expanded range of therapeutic options for these patients.
However, issues of venous access, intracardiac shunts, and
thromboembolic risk will often preclude a transvenous
approach for lead implantation, and an epicardial approach
may need to be considered. Data from current automatic
implantable cardioverter-defibrillator trials in patients with
ischemic or dilated cardiomyopathy appear to support ex-
panded indications for automatic implantable cardioverter-
defibrillator use in patients with substantial ventricular
dysfunction, nonsustained ventricular tachycardia, and in-
ducible ventricular tachycardia according to the electro-
physiologic study. It is possible that these results may be
extrapolated to adults with CHD, suggesting that the rate ofFigure 4. Age range of patients with CHD in two tertiary care centers.
Table 8. Cardiac Surgery for Congenital Heart Disease* by
Major Diagnosis†
Age >16 Years
(n)
Atrial septal defect 131
Bicuspid aortic valves 129
Other diagnoses 28
Pulmonary atresia 23
Tetralogy of Fallot 20
Ebstein’s anomaly 11
Transposition of the great arteries 10
Atrioventricular canal 9
Coarctation of the aorta 9
Double-outlet right ventricle 5
Anomalous pulmonary venous connection 4
Double-inlet left ventricle 4
Patent ductus arteriosus 3
Tricuspid atresia 2
Ventricular septal defect 2
Truncus arteriosus 1
Total 391
*Performed at the Mayo Clinic, Rochester, Minnesota, in 1999. †Includes all
congenital diagnoses and all bicuspid aortic valve repairs.
The patients’ mean age was 36.1 years (oldest patient 86 years).
Figure 3. Outpatient attendance for 1997, according to age .16 years,
basic diagnosis, and age. AR 5 aortic regurgitation; ASD 5 atrial septal
defect; A-V 5 atrioventricular; DORV 5 double-outlet right ventricle;
MV 5 mitral valve; SUB AS 5 subaortic stenosis; VSD 5 ventricular
septal defect. Statistics from Jane Somerville, London, U.K.
1174 Warnes and Liberthson JACC Vol. 37, No. 5, 2001
Task Force 1: The Changing Profile of Congenital Heart Disease in Adult Life April 2001:1161–98
automatic cardioverter-defibrillator implantation will con-
tinue to increase in this patient population.
Catheterization/Intervention. Cardiac catheterization has
been the diagnostic “gold” standard for CHD for the past 50
years. For the past 20 years, it has been increasingly
supplemented by noninvasive diagnostic modalities; ini-
tially, cardiac ultrasound and, more recently, computed
tomographic scanning and magnetic resonance imaging.
Advances in these technologies have been logarithmic, and
it is likely that in the coming decade, both morphologic and
functional assessments of this patient population will be
increasingly accomplished noninvasively.
Today, diagnostic catheterization is largely reserved for
resolution of specific issues concerning operative interven-
tions, including: 1) the preoperative evaluation of coronary
arteries; 2) the assessment of pulmonary vascular disease and
its response to vasoactive agents for planned, traditional
surgical intervention and/or heart or heart/lung transplan-
tation; and 3) as an adjunct to the noninvasive assessment of
the morphologic and functional characteristics of many
complex congenital lesions (e.g., delineation of arterial and
venous anatomy, patients with heterotaxy, Fontan candi-
dates, and patients who have had previous palliation in the
form of a shunt). Such procedures should be performed by
experienced and trained operators who maintain an ade-
quate minimal volume annually.
Evaluation for possible interventional catheterization has
become an increasingly common indication for diagnostic
catheterization. For some lesions, notably valvular pulmo-
nary stenosis, branch pulmonary stenosis, residual or recur-
rent aortic coarctation, and arteriovenous fistulae, catheter
intervention is widely considered to be the treatment of
choice. Coil or device occlusion of the patent ductus
produces results comparable to those of surgical closure, and
device closure of secundum atrial septal defects is often
employed, although the success rate varies with operator
expertise and the specific device used. It is likely that
technical problems related to these devices will ultimately be
overcome. Dilation of stenotic palliative shunts can obviate
the need for re-operation, and transcatheter occlusion of
shunts before repair of intracardiac lesions may simplify the
surgical procedure. Along with the growth of interventional
catheterization, there has been a renewed interest in small-
incision cardiac surgery, and there will likely be continued
advocacy for both management alternatives. Finally, a na-
tional and global perspective must be kept in mind, relative
to limited resources in developing regions where interven-
tional catheterization may provide partial or definitive treat-
ment for many patients with CHD who do not have access
to cardiac surgery.
Echocardiography. With improvements and refinements
in echocardiographic technology, most adults attending an
outpatient clinic undergo transthoracic echocardiography
and, when necessary, complementary transesophageal echo-
cardiography and magnetic resonance imaging. Two-
dimensional imaging is more challenging in this patient
population because of larger body size and often multiple
previous surgical scars. The use of transesophageal echocar-
diography intraoperatively is also increasing, and it has been
shown that it has a major impact on cardiac surgical
procedures in 6% to 9% of cases (i.e., that it is desirable or
necessary for the patient to resume cardiopulmonary bypass
for revision of the cardiac procedure). Physicians interpret-
ing these echocardiograms need to be experienced and have
expertise in all aspects of CHD.
A high rate of diagnostic errors in pediatric echocardio-
grams performed in community-based adult laboratories has
been reported (8). This study reported patients of varying
ages, from one day to 18 years, and either interpretive or
technical errors that were of major or moderate importance
occurred in 53% of cases. There is reason to believe that in
older patients, errors occur even more frequently because
image acquisition is more challenging. Clearly, both exper-
tise and technology are necessary to provide the best care.
Conclusions. The data, estimates, and models described
herein emphasize that patients in the U.S. have been
underserved by the present health care system. Over the
next decade, a more comprehensive system must be devel-
oped for this growing population, with considerable collab-
oration between cardiologists specializing in pediatrics and
adults. This Conference will facilitate the further recogni-
tion of these needs and hopefully help to develop the
resources needed to achieve these objectives.
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